This is a database of the academic work published by our staff and students. The full text of many of our journal articles is available free of charge from this website.

  • Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. 

    Tutt, ANJ; Garber, JE; Kaufman, B; Viale, G; Fumagalli, D; Rastogi, P; Gelber, RD; de Azambuja, E; Fielding, A; Balmaña, J; Domchek, SM; Gelmon, KA; Hollingsworth, SJ; Korde, LA; Linderholm, B; Bandos, H; Senkus, E; Suga, JM; Shao, Z; Pippas, AW; Nowecki, Z; Huzarski, T; Ganz, PA; Lucas, PC; Baker, N; Loibl, S; McConnell, R; Piccart, M; Schmutzler, R; Steger, GG; Costantino, JP; Arahmani, A; Wolmark, N; McFadden, E; Karantza, V; Lakhani, SR; Yothers, G; Campbell, C; Geyer, CE; OlympiA Clinical Trial Steering Committee and Investigators (2021-06-03)
    <h4>Background</h4>Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients ...
  • Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. 

    Johnston, S; O'Shaughnessy, J; Martin, M; Huober, J; Toi, M; Sohn, J; André, VAM; Martin, HR; Hardebeck, MC; Goetz, MP (2021-06-22)
    In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data for clinically prognostic ...
  • The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)-A Protocol for an International Cohort Study. 

    Schut, A-RW; Timbergen, MJM; Lidington, E; Grünhagen, DJ; van der Graaf, WTA; Sleijfer, S; van Houdt, WJ; Bonenkamp, JJ; Younger, E; Dunlop, A; Jones, RL; Verhoef, C; Gennatas, S; Husson, O (2021-06-22)
    Sporadic desmoid-type fibromatosis (DTF) is a rare soft tissue tumour with an unpredictable clinical course. These tumours are incapable of metastasising, but their local aggressive tumour growth and tendency to recur ...
  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. 

    Sartor, O; de Bono, J; Chi, KN; Fizazi, K; Herrmann, K; Rahbar, K; Tagawa, ST; Nordquist, LT; Vaishampayan, N; El-Haddad, G; Park, CH; Beer, TM; Armour, A; Pérez-Contreras, WJ; DeSilvio, M; Kpamegan, E; Gericke, G; Messmann, RA; Morris, MJ; Krause, BJ; VISION Investigators (2021-06-23)
    <h4>Background</h4>Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. ...
  • Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. 

    Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; Song, YK; Yohe, ME; Sindiri, S; Wei, J; Wen, X; Rudzinski, ER; Barkauskas, DA; Lo, T; Hall, D; Linardic, CM; Hughes, D; Jamal, S; Jenney, M; Chisholm, J; Brown, R; Jones, K; Hicks, B; Angelini, P; George, S; Chesler, L; Hubank, M; Kelsey, A; Gatz, SA; Skapek, SX; Hawkins, DS; Shipley, JM; Khan, J
    <h4>Purpose</h4>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond ...

View more